Articles from: PPHM (Peregrine Pharmaceuticals Inc) (MSN Money)
 |
|
|
|
|
| Next Page
| |
|
| Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recu (more) | 2011 05 19 |
|
|
| Four AACR Presentations Highlight Broad Therapeutic and Diagnostic Potentia (more) | 2011 04 06 |
|
|
| Peregrine's PS-Targeting Antibody Significantly Improves Anti-Tumor Effect (more) | 2011 04 05 |
|
|
|
| Peregrine Presents Phase Ib HCV/HIV Data on Single-Agent Bavituximab at EAS (more) | 2011 04 04 |
|
|
|
| Peregrine Pharmaceuticals' CEO Discusses Q3 2011 Results - Earnings Call T (more) | 2011 03 12 |
|
| Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2011 Financial (more) | 2011 03 11 |
|
| Peregrine Pharmaceuticals to Present at Roth Capital Partners OC Growth Sto (more) | 2011 03 10 |
|
| Avid Bioservices to Present Comparability Studies of Large-Scale Manufactur (more) | 2011 03 09 |
|
| Peregrine Appoints Head of Medical Oncology as Company Advances Four Random (more) | 2011 03 09 |
|
| Peregrine Announces Initiation of Lung Cancer Investigator-Sponsored Trial (more) | 2011 03 08 |
|
| Peregrine's Bavituximab HCV Abstract Accepted for Presentation at the 46th (more) | 2011 03 07 |
|
| Peregrine to Report Third Quarter Fiscal Year 2011 Financial Results After (more) | 2011 03 04 |
|
| Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual (more) | 2011 02 28 |
|
|
| Peregrine Announces Initiation of Investigator-Sponsored Trial in HER2-Nega (more) | 2011 02 06 |
|
|
| Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection Tria (more) | 2011 01 31 |
|
| Peregrine Announces Initiation of Investigator-Sponsored Trial in HER2-Nega (more) | 2011 01 19 |
|
|
|
| Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hep (more) | 2011 01 10 |
|
|
| Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic (more) | 2011 01 05 |
|
| Anadarko, Corinthian Colleges, Peregrine, VisionChina: U.S. Equity Movers (more) | 2010 12 30 |
|
|
| Bank Mutual, D.R. Horton, Duke Realty, KB Home, Lennar: U.S. Equity Movers (more) | 2010 12 20 |
|
| Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain C (more) | 2010 12 20 |
|
| Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2011 Financial (more) | 2010 12 10 |
|
|
| Peregrine to Report Second Quarter Fiscal Year 2011 Financial Results After (more) | 2010 12 02 |
|
| Peregrine Announces Initiation of Phase I/II Investigator-Sponsored Trial i (more) | 2010 12 01 |
|
|
| Avid Bioservices to Present at IBC'S Antibody Engineering & Therapeutics Co (more) | 2010 11 29 |
|
| Peregrine's Bavituximab Demonstrates Broad Potential in Viral Hemorrhagic F (more) | 2010 11 17 |
|
|
| Peregrine Awarded $977,917 Grant Under IRS Section 48D for Qualifying Thera (more) | 2010 11 02 |
|
| Avid Bioservices to Present at IBC's Preclinical Scale Bioprocessing Confer (more) | 2010 10 25 |
|
|
| Peregrine Appoints Chairman of the Board and Announces Results From Annual (more) | 2010 10 21 |
|
| Peregrine to Present Bavituximab Antiviral Data at 2010 Chemical and Biolog (more) | 2010 10 20 |
|
|
| Peregrine Reports Promising Interim Survival Data From Phase II Cotara(R) B (more) | 2010 10 18 |
|
|
| Next Page
| |
